HNGR Hanger Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Campbell James H	2. Issuer Name and Ticker or Trading Symbol HANGER, INC. [ HNGR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) SVP, Chief Clinical Officer
(Last)          (First)          (Middle) 10910 DOMAIN DRIVE, SUITE 300	3. Date of Earliest Transaction (MM/DD/YYYY) 5/19/2020
(Street) AUSTIN, TX 78758 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	5/19/2020		A(1)		16841	A	$0	43446	D
Common Stock	5/19/2020		F(2)		5785	D	$17.12	37661 (3)(4)(5)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$12.77							(6)	5/19/2027	Common Stock	27328		27328	D

Explanation of Responses:
(1)	Shares received pursuant to the Company's Special Equity Plan as a result of the vesting of PSUs awarded in 2017 due to the achievement of predetermined levels of absolute common stock price compounded annual growth period over the three-year performance period.
(2)	Reflects payment of tax liability by withholding shares of stock incident to vesting of performance shares.
(3)	Consists of (i) unvested restricted shares totaling 4,556 shares of stock from an initial grant of 4,556 shares of restricted stock that begins to vest on March 9, 2021; (ii) unvested restricted shares and fully vested shares totaling 4,026 shares of stock from an initial grant of 4,405 shares of restricted stock made on March 8, 2019; (iii) unvested restricted shares and fully vested shares totaling 4,771 shares of stock from an initial grant of 5,220 shares of restricted stock made on March 8, 2019; (iv) unvested restricted shares and fully vested shares totaling 5,691 shares of stock from an initial grant of 6,710 shares of restricted stock made on March 9, 2018; (v) unvested restricted shares and fully vested shares totaling 4,220 shares of stock from an initial grant of 7,029 shares of restricted stock made on March 8, 2017; [continued in next footnote]
(4)	(vi) unvested restricted shares and fully vested shares totaling 1,316 shares of stock from an initial grant of 3,000 shares of restricted stock made on October 11, 2016; and (vii) unvested restricted shares and fully vested shares totaling 2,025 shares of stock from an initial grant of 6,008 shares of restricted stock made on April 29, 2016.
(5)	Except as otherwise noted, all remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant.
(6)	Stock options were granted under the Company's Special Equity Plan and vest 1/3 on each of May 19, 2018, 2019 and 2020.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Campbell James H 10910 DOMAIN DRIVE, SUITE 300 AUSTIN, TX 78758			SVP, Chief Clinical Officer

Signatures
/s/ Jessica Lochmann Allen, Attorney-in-Fact for James H. Campbell		5/21/2020
**Signature of Reporting Person		Date